Burning Rock Biotech (NASDAQ:BNR – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Burning Rock Biotech to similar businesses based on the strength of its profitability, risk, institutional ownership, analyst recommendations, valuation, dividends and earnings.
Insider & Institutional Ownership
30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Burning Rock Biotech has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Burning Rock Biotech’s rivals have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Burning Rock Biotech | 1 | 0 | 0 | 0 | 1.00 |
| Burning Rock Biotech Competitors | 9924 | 15317 | 45695 | 1603 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 131.26%. Given Burning Rock Biotech’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Burning Rock Biotech has less favorable growth aspects than its rivals.
Profitability
This table compares Burning Rock Biotech and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Burning Rock Biotech | -13.60% | -12.98% | -8.59% |
| Burning Rock Biotech Competitors | -12,319.70% | -407.93% | -30.95% |
Earnings & Valuation
This table compares Burning Rock Biotech and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Burning Rock Biotech | $77.16 million | -$7.92 million | -14.64 |
| Burning Rock Biotech Competitors | $690.32 million | $9.48 million | -18.32 |
Burning Rock Biotech’s rivals have higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Burning Rock Biotech rivals beat Burning Rock Biotech on 7 of the 13 factors compared.
About Burning Rock Biotech
Burning Rock Biotech is a precision oncology company that develops and provides next-generation sequencing tests for cancer. Its testing uses tissue and blood samples to help inform treatment decisions, monitor disease and support cancer research. The company also provides research and clinical-trial services to pharmaceutical companies, including support for the development of cancer therapies and diagnostic tests. Burning Rock is headquartered in Guangzhou, China, and its business primarily serves the Chinese healthcare and life sciences markets.
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
